The Laryngoscope · 2005 · 110 citations · 20 references
MedicineOtolaryngologyBone MetabolismHearing ScienceOtologyBone HistomorphometryBone PathologyBone PhysiologyEar AnatomyOsteoclast BiologyOsteogenesisBone BiologyInner Ear PhysiologyNuclear Factor Kappa B ActivationNuclear Factor Kappa B InhibitionOsteoprotegerin RegulationOsteoprotegerin SignalingRank Ligand InhibitionRankl-opg Signaling Axis
OBJECTIVES: To elucidate factors that may be responsible for the inhibition of remodeling of bone within the otic capsule. METHODS: Expression of osteoprotegerin (OPG), receptor activator of nuclear factor kappa B (RANK), and RANK ligand (RANKL) were assayed in samples of bone obtained from the otic capsule, calvarium, and femur, and from the soft tissue within the cochlea using semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) in mice. Immunostaining was used for histologic localization of the gene products. An enzyme-linked immunosorbent assay (ELISA) was used to quantify the amount of OPG within perilymph, serum, and cerebrospinal fluid. The micro-anatomy of the interface between the otic capsule and the fluid spaces of the cochlea was investigated by brightfield and phase-contrast microscopy and by three-dimensional reconstruction in the mouse and human. RESULTS: OPG, a powerful inhibitor of bone remodeling, was expressed at extremely high levels within the soft tissue of the cochlea and was present in the perilymph at very high concentrations. The OPG produced within the inner ear may diffuse into the surrounding otic capsule, where it may be responsible for inhibition of bone turnover. Our anatomic studies revealed an extensive system of interconnected canaliculi within the otic capsule that had direct openings into the fluid spaces of the inner ear, thus providing a possible anatomic route for the diffusion of OPG from the inner ear into the surrounding bone. CONCLUSION: OPG, a potent inhibitor of osteoclast formation and function, is expressed at high levels within the inner ear and is secreted into the perilymph and the surrounding bone and may serve to inhibit active bone remodeling within the otic capsule, especially immediately adjacent to the cochlea. By this means, the cochlear soft tissue may control the nature of the surrounding petrous bone.
20
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation
David L. Lacey, Emma Timms, Hong‐Lin Tan et al. · Cell · 1998 · 5.5K citations · Full text
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density
W. Scott Simonet, Dave Lacey, Colin R. Dunstan et al. · Cell · 1997 · 5.1K citations · Full text
Hailing Hsu, David L. Lacey, Colin R. Dunstan et al. · Proceedings of the National Academy of Sciences · 1999 · 1.6K citations
The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts
Teresa L. Burgess, Yixin Qian, Stephen A. Kaufman et al. · The Journal of Cell Biology · 1999 · 692 citations · Full text